HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: dc07-1424v1 31/2/328    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Google Scholar Articles by Glintborg, D. Articles by Handberg, A. PubMed PubMed Citation Articles by Glintborg, D. Articles by Handberg, A. Social Bookmarking                What's this?

Soluble CD36 and Risk Markers of Insulin Resistance and Atherosclerosis Are Elevated in Polycystic Ovary Syndrome and Significantly Reduced During Pioglitazone Treatment

¹ Department of Endocrinology and Metabolism, Odense University Hospital, Odense, Denmark
² Clinical Biochemical Department, Aarhus University Hospital, Aarhus, Denmark

Address correspondence and reprint requests to Dorte Glintborg, Kløvervanget 6, 3rd floor, DK-500 Odense, Denmark. E-mail: dorte.glintborg{at}dadlnet.dk

OBJECTIVE—We investigated the relation between soluble CD36 (sCD36), risk markers of atherosclerosis and body composition, and glucose and lipid metabolism in polycystic ovary syndrome (PCOS).

RESEARCH DESIGN AND METHODS—Thirty PCOS patients were randomized to 30 mg/day pioglitazone or placebo for 16 weeks. Fourteen weight-matched healthy female subjects were included as control subjects. sCD36, oxidized LDL (oxLDL), high-sensitivity C-reactive protein (hsCRP), interleukin (IL)-6, euglycemic-hyperinsulinemic clamps, and whole-body dual-energy X-ray absorptiometry scans were performed.

RESULTS—sCD36 (2.87 relative units [0.88–9.36] vs. 1.67 relative units [0.72–3.89]), oxLDL (44.9 units/l [26.9–75.1] vs. 36.1 units/l [23.4–55.5]), and hsCRP (0.26 mg/dl [0.03–2.41] vs. 0.12 mg/dl [0.02–0.81]) were significantly increased in PCOS patients versus control subjects (geometric mean ± 2 SD). In PCOS, positive correlations were found between central fat mass and sCD36 (r = 0.43), hsCRP (r = 0.43), and IL-6 (r = 0.42) (all P < 0.05). After adjusting for fat mass, sCD36 and oxLDL correlated inversely with measures of insulin-stimulated glucose metabolism and positively with lipid oxidation during insulin stimulation in PCOS patients and control subjects (n = 44). sCD36 and oxLDL were significant independent predictors of glucose and lipid metabolism, whereas hsCRP and IL-6 showed no significant contribution. Following pioglitazone treatment, insulin sensitivity increased, whereas sCD36 (3.21 relative units [0.76–13.6] vs. 2.33 relative units [0.84–6.46]) and hsCRP decreased (P < 0.05). No significant changes were measured in body composition.

CONCLUSIONS—sCD36 and oxLDL correlated with measures of insulin sensitivity independent of central fat mass. Pioglitazone treatment reduced sCD36 while improving insulin-stimulated glucose metabolism, further supporting the association between sCD36 and insulin resistance in PCOS.

Abbreviations: ELISA, enzyme-linked immunosorbent assay • FFA, free fatty acid • hsCRP, high-sensitivity C-reactive protein • IL, interleukin • oxLDL, oxidized LDL • PCOS, polycystic ovary syndrome • sCD36, soluble CD36

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?